The advent of biosimilar medications has offered the promise of significant cost savings for healthcare systems and patients. Biosimilars are highly similar versions of existing biologic drugs, providing a more affordable alternative once the original biologic patent expires. However, the adoption of biosimilars in the U.S. has been hampered by myriad roadblocks, many of which…
At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.
A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.
Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
At the ARP Keynote lecture at ACR Convengence 2024, Sandra Mintz, RN, MS, discussed the importance of empathy & trust-building between doctors & their rheumatology patients.
At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.
As rheumatology care evolves into a team-based approach, the workforce is expanding to incorporate advanced practice providers, physical therapists and social workers, all of whom can play vital roles in patient care.
ARP members honored for significant contributions to rheumatology research, education and patient care.
The ACR honored 19 members for outstanding contributions to the ACR and the field of rheumatology.
The 2024 Dubois Memorial Lecture focused on health inequities with lupus & strategies to close the gap.